Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | F13A1 | P00488 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4870688 | 0.99 | AOC3 (0.52) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4582523 | 0.88 | ALDH1A1 (0.56) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6331116 | 0.83 | NPC1 (0.58) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL8152325 | 0.83 | LTA4H (0.52) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| Bromide SCHEMBL8146099 | 0.82 | LTA4H (0.51) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8148068 | 0.81 | LTA4H (0.58) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8146339 | 0.80 | ALDH1A1 (0.51) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3278932 | 0.79 | NPC1 (0.56) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10519209 | 0.77 | ALDH1A1 (0.76) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4987302 | 0.77 | AOC3 (0.65) | ALDH1A1MEN1KMT2AMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | LTA4H 921/4885ALDH1A1 927/4885KDM4E 3439/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | LTA4H 2428/4885ALDH1A1 930/4885KDM4E 3386/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | LTA4H 750/4885ALDH1A1 260/4885KDM4E 2818/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | LTA4H 2428/4885ALDH1A1 930/4885KDM4E 3386/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | LTA4H 3145/4885ALDH1A1 1690/4885KDM4E 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.